Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Cytokine Profiling in Antiphospholipid Syndrome Demonstrates Persistent Immune Dysregulation and a Procoagulant Phenotype

Anne K Hubben, Peter Bazeley, Shadi Swaidani, Ahmed Alarabi, Paresh P Kulkarni, Young Jun Shim, Maierdan Palihati, John Barnard, Keith R. McCrae

Blood (2023) 142 (Supplement 1): 5400.

https://doi.org/10.1182/blood-2023-187962

Published: 2023

Journal Articles

Differential Isoforms Signature of Splicing Factor Mutant Myeloid Neoplasia

Arda Durmaz, Carmelo Gurnari, Carlos Bravo-Perez, Luca Guarnera, Yasuo Kubota, Naomi Kawashima, Ishani Nautiyal, Sean Yetter, Nakisha D Williams, Serhan Unlu, Sindhusha Veeraballi, Arooj Ahmed, Chao-Yie Yang, John Barnard, Jacob Scott, Jaroslaw P. Maciejewski, Valeria Visconte

Blood (2023) 142 (Supplement 1): 5701.

https://doi.org/10.1182/blood-2023-184752

Published: 2023

Journal Articles

Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia

Arda Durmaz, Carmelo Gurnari, Courtney E. Hershberger, Simona Pagliuca, Hassan Awada, Hussein Awada, Minako Mori, Yasuo Kubota, Tariq Kewan, Waled Bahaj, John Barnard, Jacob Scott, Richard A Padgett, Torsten Haferlach, Jaroslaw P. Maciejewski, Valeria Visconte

Blood (2022) 140 (Supplement 1): 1917–1918.

https://doi.org/10.1182/blood-2022-164731

Published: 2022

Journal Articles

Deficiency of RPS14 Beyond the Haploinsufficient Loss in Del(5q)

Vera Adema, Sunisa Kongkiatkamon, Laura Palomo, Wencke Walter, Stephan Hutter, Thomas LaFramboise, Maria Diez-Campelo, Mar Mallo, Blanca Xicoy, Manja Meggendorfer, Hetty E. Carraway, Claudia Haferlach, Valeria Visconte, Francesc Sole, John Barnard, Torsten Haferlach, Jaroslaw P. Maciejewski

Blood (2021) 138 (Supplement 1): 2591.

https://doi.org/10.1182/blood-2021-151926

Published: 2021

Journal Articles

Novel Synthetic Lethal Targets for Myeloid Neoplasms with Loss of Chromosome 7

Minako Mori, Vera Adema, Carmelo Gurnari, Simona Pagliuca, Laila Terkawi, Waled Bahaj, Tariq Kewan, John Barnard, Valeria Visconte, Torsten Haferlach, Jaroslaw P. Maciejewski

Blood (2021) 138 (Supplement 1): 3346.

https://doi.org/10.1182/blood-2021-152974

Published: 2021

Journal Articles

Molecular and Expression Characterization of Monosomy 7 and Del(7q)

Vera Adema, PhD, Cassandra M Kerr, MS, Hassan Awada, MD, Sunisa Kongkiatkamon, MD, Bhumika J. Patel, MD, Mikkael A. Sekeres, MD MS, Valeria Visconte, PhD, John Barnard, Jaroslaw P. Maciejewski, MD PhD, Torsten Haferlach, MD

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-142507

Published: 2020

Journal Articles

Identifying miRNA Biomarkers and Predicted Targets Associated with Venous Thromboembolism in Colorectal Cancer Patients

Ann S. Kim, BA, Matthew F Kalady, MD, Jennifer DeVecchio, Kahraman Tanriverdi, Jane E. Freedman, MD, John Barnard, PhD, Tae Hyun Hwang, PhD, Alok A Khorana, MD, Keith R McCrae, MD

Blood (2019) 134 (Supplement_1): 3643.

https://doi.org/10.1182/blood-2019-127585

Published: 2019

Journal Articles

Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes

David P. Steensma, MD, Rami S. Komrokji, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Andrew M. Brunner, MD, Richard M. Stone, MD, John Barnard, PhD, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 4374.

https://doi.org/10.1182/blood-2018-99-117538

Published: 2018

Journal Articles

Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)

Blood (2017) 130 (Supplement 1): 3385.

https://doi.org/10.1182/blood.V130.Suppl_1.3385.3385

Published: 2017

Journal Articles

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (MDS)

Aziz Nazha, MD, Rami S. Komrokji, MD, John Barnard, PhD, Karam Al-Issa, MD, Eric Padron, MD, Yazan F. Madanat, MD, Teodora Kuzmanovic, BA, Nour Abuhadra, MD, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Guillermo Garcia-Manero, MD, Alan F. List, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Mikkael A. Sekeres, MD MS

Blood (2017) 130 (Supplement 1): 160.

https://doi.org/10.1182/blood.V130.Suppl_1.160.160

Published: 2017

Journal Articles

Outcomes of Myelodysplastic Syndromes (MDS) Patients with Chromosome 17 Abnormalities: A Report on Behalf of the MDS Clinical Research Consortium (MDSCRC)

Rami S. Komrokji, MD, Najla Al Ali, M.Sc, John Barnard, PhD, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, David A Sallman, MD, Eric Padron, MD, Aziz Nazha, MD, Alan F List, MD, Guillermo Garcia-Manero, MD, Mikkael A. Sekeres, MD MS

Blood (2017) 130 (Supplement 1): 4246.

https://doi.org/10.1182/blood.V130.Suppl_1.4246.4246

Published: 2017

Journal Articles

Prediction of Clinically Relevant Mutations in (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

Sangmin Lee, MD, John Barnard, PhD, Rami S. Komrokji, MD, Amy E. DeZern, MD, David P. Steensma, MD, Jaroslaw P. Maciejewski, PhD MD FACP, Ellen K Ritchie, MD, Pinkal Desai, MDMPH, Felix Tavernier, MD, Duane C. Hassane, PhD, Guillermo Garcia-Manero, MD, Mikkael A. Sekeres, MD MS, Gail J. Roboz, MD

Blood (2017) 130 (Supplement 1): 2965.

https://doi.org/10.1182/blood.V130.Suppl_1.2965.2965

Published: 2017

Journal Articles

Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS)

Aziz Nazha, MD, Mikkael A. Sekeres, MD MS, Rafael Bejar, MD PhD, Rami S. Komrokji, MD, John Barnard, PhD, Karam Al-Issa, MD, Bartlomiej P. Przychodzen, MSc, Cassandra M. Hirsch, BS, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Guillermo Garcia-Manero, MD, Benjamin L. Ebert, MD PhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 157.

https://doi.org/10.1182/blood.V130.Suppl_1.157.157

Published: 2017

Journal Articles

Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes (MDS): Are They Two Faces of the Same Coin? a Study on Behalf of the MDS Clinical Research Consortium (MDS CRC)

Rami S. Komrokji, MD, John Barnard, PhD, David P Steensma, MD, Amy E. DeZern, MD MHS, Gail J. Roboz, Najla Alali, MS, Jaime Fensterl, Guillermo Garcia-Manero, MD, Mikkael A. Sekeres, MD MS

Blood (2016) 128 (22): 4321.

https://doi.org/10.1182/blood.V128.22.4321.4321

Published: 2016

Journal Articles

Targeting Autophagy in Myelodysplastic Syndromes

Valeria Visconte, PhD, Steffan T. Nawrocki, PhD, Bartlomiej P Przychodzen, MSc, Kevin R. Kelly, MD PhD, Mei Yin, Yvonne Parker, Michael J. Clemente, M.S., John Barnard, PhD, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Daniel Lindner, Heesun J Rogers, MD PhD, Jaroslaw P Maciejewski, MD PhD FACP, Jennifer S. Carew, PhD

Blood (2016) 128 (22): 4295.

https://doi.org/10.1182/blood.V128.22.4295.4295

Published: 2016

Journal Articles

Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)

Aziz Nazha, MD, Rami S. Komrokji, MD, John Barnard, PhD, Najla H Al Ali, Gail J. Roboz, David P. Steensma, MD, Amy E. DeZern, MD MHS, Jaime Fensterl, Guillermo Garcia-Manero, MD, Alan F List, MD, Jaroslaw P Maciejewski, MD PhD FACP, Mikkael A. Sekeres, MD MS

Blood (2016) 128 (22): 4332.

https://doi.org/10.1182/blood.V128.22.4332.4332

Published: 2016

Journal Articles

Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

Sangmin Lee, MD, John Barnard, PhD, Amy E. DeZern, MD MHS, Jaroslaw P Maciejewski, MD PhD FACP, Najla Alali, MS, David P. Steensma, MD, Ellen K. Ritchie, MD, Pinkal Desai, MD, Guillermo Garcia-Manero, MD, Fatima Ali, B.S., Nicole Rizzo, BA, Duane C Hassane, PhD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Gail J. Roboz

Blood (2016) 128 (22): 297.

https://doi.org/10.1182/blood.V128.22.297.297

Published: 2016

Journal Articles

Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating Agents in Myelodysplastic Syndromes

Aziz Nazha, MD, Mikkael A. Sekeres, MD MS, Rafael Bejar, MD PhD, John Barnard, PhD, Karam Al-Issa, MD, Bartlomiej P Przychodzen, MSc, Matt Kalaycio, MD, Michael J. Clemente, M.S., Cassandra M. Hirsch, BSc, Benjamin L Ebert, MD PhD, Jaroslaw P. Maciejewski

Blood (2016) 128 (22): 3193.

https://doi.org/10.1182/blood.V128.22.3193.3193

Published: 2016

Journal Articles

Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, John Barnard, PhD, Najla Alali, MS, Amy E. DeZern, MD MHS, Eric Padron, MD, David Sallman, MD, Jeffrey E. Lancet, MD, Gail J. Roboz, Jaime Fensterl, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Alan F List, MD

Blood (2016) 128 (22): 4322.

https://doi.org/10.1182/blood.V128.22.4322.4322

Published: 2016

Journal Articles

Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)

Amy E. DeZern, MD, Amer M. Zeidan, MBBS, MHS, John Barnard, PhD, Wesley Hand, Najla Al Ali, Francis Brown, Cassie Zimmerman, MPH, Gail J Roboz, MD, Rami S. Komrokji, MD, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Mikkael A. Sekeres, MD MS

Blood (2015) 126 (23): 2889.

https://doi.org/10.1182/blood.V126.23.2889.2889

Published: 2015

NARROW

Cytokine Profiling in Antiphospholipid Syndrome Demonstrates Persistent Immune Dysregulation and a Procoagulant Phenotype

Differential Isoforms Signature of Splicing Factor Mutant Myeloid Neoplasia

Multi-Omics Data Integration of Genomics and RNA-Splicing in Myeloid Neoplasia

Deficiency of RPS14 Beyond the Haploinsufficient Loss in Del(5q)

Novel Synthetic Lethal Targets for Myeloid Neoplasms with Loss of Chromosome 7

Molecular and Expression Characterization of Monosomy 7 and Del(7q)

Identifying miRNA Biomarkers and Predicted Targets Associated with Venous Thromboembolism in Colorectal Cancer Patients

Disparities in Participation in Interventional Clinical Trials for Myelodysplastic Syndromes

Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)

A Personalized Prediction Model to Risk Stratify Patients with Myelodysplastic Syndromes (MDS)

Outcomes of Myelodysplastic Syndromes (MDS) Patients with Chromosome 17 Abnormalities: A Report on Behalf of the MDS Clinical Research Consortium (MDSCRC)

Prediction of Clinically Relevant Mutations in (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

Genomic Biomarkers to Predict Response to Hypomethylating Agents in Patients with Myelodysplastic Syndromes (MDS)

Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes (MDS): Are They Two Faces of the Same Coin? a Study on Behalf of the MDS Clinical Research Consortium (MDS CRC)

Targeting Autophagy in Myelodysplastic Syndromes

Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)

Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)

Using Machine Intelligence Algorithms to Develop a Geno-Clinical Model to Predict Responses to Hypomethylating Agents in Myelodysplastic Syndromes

Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Differential Response to Hypomethylating Agents Based on Sex: A Report on Behalf of the MDS Clinical Research Consortium (MDS CRC)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only